34 mainland China biotechs file for Hong Kong IPO in H1 2025
Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange (HKEX) in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 companies were from mainland China. In June alone, 12 Chinese biotechnology, pharmaceutical and med-tech companies filed for a Hong Kong IPO including…